首页 > 市场调查报告书 > 医疗设备

医学影像诊断药物递输设备电子医疗设备内视镜检查设备

市场调查报告书

商品编码

1544188

智慧药丸市场规模、份额和成长分析：按应用、目标领域、最终用户、地区 - 产业预测，2024-2031 年

Smart Pills Market Size, Share, Growth Analysis, By Application (Capsule Endoscopy, Vital Sign Monitoring), By Target Area (Esophagus, Small Intestine), By End User (Hospitals, Diagnostic Centers), By Region - Industry Forecast 2024-2031

出版日期: 2024年08月23日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球智慧药丸市场规模为47亿美元，从2023年的53.2亿美元成长到2031年的139.5亿美元，预计在预测期间（2024-2031年）复合年增长率为12.8%。

全球智慧药丸市场正在迅速发展，具有改变医疗保健的巨大潜力。智慧药丸，也称为数位药丸或可摄入感测器，是嵌入小型电子设备的胶囊，吞服后可以在体内进行即时监控和资料传输。这些创新锭剂旨在透过改善诊断和优化治疗结果来增强患者护理。其目标是弥合医疗技术和患者监测之间的差距，为管理各种健康状况提供非侵入性且便捷的解决方案。智慧药丸可以追踪用药依从性、监测生命征象、检测异常情况并将关键资料即时发送给医疗专业人员。有几个因素正在推动智慧药丸市场的成长，使其成为一个令人兴奋的领域。心血管疾病、糖尿病、胃肠道疾病等慢性疾病的增加需要持续监测和及时干预。智慧药丸为疾病管理和早期发现併发症提供了新方法，从而改善了患者的治疗效果。此外，不断增长的老年人口和对远端患者监护的需求正在刺激智慧药丸的采用。微电子和无线通讯的技术进步正在改善智慧药丸的功能。改进的感测器和连接性使得全面的生理资料收集成为可能，例如温度、pH 水平和药物释放模式，从而促进准确的诊断和个人化治疗。儘管潜力巨大，但该市场仍面临隐私问题、监管障碍、高成本以及医疗保健专业人员和患者意识有限等挑战。然而，人工智慧 (AI) 和机器学习与智慧药丸的融合等新趋势为即时资料分析和个人化治疗提供了机会。製药公司、技术公司和医疗保健提供者之间的合作也正在推动创新和产品开发。这些发展为相关人员提供了加强药物开发、优化临床试验、降低医疗成本以及改善病人参与和结果的机会。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Medtronic PLC（Ireland）
Proteus Digital Health Inc.（US）
CapsoVision Inc.（US）
Olympus Corporation（Japan）
Medisafe（US）
Bio-Images Research Limited（UK）
BodyCap（France）
Given Imaging Ltd.（Israel）
Philips Healthcare（Netherlands）
Medimetrics Personalized Drug Delivery BV（Netherlands）
PENTAX Medical（Japan）
Proteus Biomedical（US）
Check-Cap Ltd.（Israel）
Smart Pill Corporation（US）
IntroMedic Co. Ltd.（South Korea）
Acamp AG（Switzerland）
Olympus Medical Systems Corporation（Japan）
Medisim Ltd.（Israel）
Medtronic Inc.（US）
Medimetrics SA（Belgium）

简介目录

Product Code: SQMIG35I2313

Global Smart Pills Market size was valued at USD 4.7 billion in 2022 and is poised to grow from USD 5.32 billion in 2023 to USD 13.95 billion by 2031, at a CAGR of 12.8% during the forecast period (2024-2031).

The Global Smart Pills Market is rapidly advancing and holds significant potential to transform healthcare. Also known as digital pills or ingestible sensors, smart pills are capsules embedded with tiny electronic devices that, once swallowed, enable real-time monitoring and data transmission from within the body. These innovative pills are designed to enhance patient care by improving diagnosis and optimizing treatment outcomes. Their purpose is to bridge the gap between medical technology and patient monitoring, offering a non-invasive and convenient solution for managing various health conditions. Smart pills can track medication adherence, monitor vital signs, detect abnormalities, and send crucial data to healthcare professionals in real time. Several factors are driving the growth of the smart pills market, making it an exciting field. The increasing prevalence of chronic diseases like cardiovascular disorders, diabetes, and gastrointestinal conditions necessitates continuous monitoring and timely intervention. Smart pills provide a novel method for disease management and early detection of complications, improving patient outcomes. Additionally, the growing elderly population and the demand for remote patient monitoring are fueling the adoption of smart pills, which help reduce hospital visits and support independent living. Technological advancements in microelectronics and wireless communication have enhanced smart pills' capabilities. Improved sensors and connectivity allow for comprehensive physiological data collection, such as temperature, pH levels, and drug release patterns, facilitating precise diagnosis and personalized treatment. Despite their potential, the market faces challenges like privacy concerns, regulatory hurdles, high costs, and limited awareness among healthcare professionals and patients. However, emerging trends such as integrating artificial intelligence (AI) and machine learning with smart pills offer opportunities for real-time data analysis and personalized care. Collaborations between pharmaceutical companies, technology firms, and healthcare providers are also driving innovation and product development. These developments present opportunities for stakeholders to enhance drug development, optimize clinical trials, reduce healthcare costs, and improve patient engagement and outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Smart Pills market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Smart Pills Market Segmental Analysis

Global smart pills market is segmented on the application, target area, end-user and region. Based on application, the market is segmented into capsule endoscopy, targeted drug delivery, and vital sign monitoring. Based on target area, the market is segmented into esophagus, small intestine, large intestine, and stomach. Based on end-users, the market is segmented into hospitals, diagnostic centers, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Smart Pills Market

The increasing prevalence of gastrointestinal disorders, including Crohn's disease, irritable bowel syndrome (IBS), and colon cancer, is a key driver for the smart pills market. Smart pills equipped with advanced sensors can offer real-time insights into the digestive system, facilitating early diagnosis, personalized treatment, and enhanced patient outcomes. As gastrointestinal diseases become more widespread globally, smart pills provide a valuable tool for detecting abnormalities, monitoring disease progression, and administering targeted therapies in a non-invasive and patient-friendly way. This capability is crucial for improving the management of these conditions and addressing the growing healthcare needs associated with gastrointestinal health.

Restraints in the Global Smart Pills Market

The high cost of smart pills is a major barrier to their widespread adoption. The sophisticated technologies and manufacturing processes required to produce these pills result in higher prices compared to traditional diagnostic methods. This cost issue can restrict the accessibility of smart pills, especially in developing regions with limited healthcare resources. The expense associated with smart pills presents challenges related to affordability and reimbursement, potentially making it difficult for patients in certain areas or with constrained financial means to benefit from this advanced diagnostic technology.

Market Trends of the Global Smart Pills Market

A key trend in the smart pills market is the integration of AI algorithms and data analytics. Utilizing machine learning and advanced data analysis techniques, smart pills can deliver valuable insights, recognize patterns, and support predictive diagnostics, thereby improving the accuracy and efficiency of disease detection and monitoring. Smart pills equipped with AI capabilities can analyze real-time data from the digestive system, identify anomalies or disease markers, and offer actionable insights to healthcare providers. This integration enables early intervention and personalized treatment, enhancing overall patient care.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors of The Market
Degree Of Competition
Top Investment Pockets
Market Attractive Index
Ecosystem Mapping
Technology Analysis
Supply Chain Analysis
Patent Analysis
Pricing Analysis
Consumer Analysis
Pipeline Analysis

Global Smart Pills Market By Application

Market Overview
Capsule Endoscopy
Targeted Drug Delivery
Vital Sign Monitoring

Global Smart Pills Market By Target Area

Market Overview
Esophagus
Small Intestine
Large Intestine
Stomach

Global Smart Pills Market By End-User

Market Overview
Hospitals
Diagnostic Centers
Others

Global Smart Pills Market Size By Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Medtronic PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Proteus Digital Health Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CapsoVision Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Olympus Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medisafe (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Images Research Limited (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BodyCap (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Given Imaging Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Philips Healthcare (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medimetrics Personalized Drug Delivery B.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PENTAX Medical (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Proteus Biomedical (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Check-Cap Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smart Pill Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IntroMedic Co. Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acamp AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Olympus Medical Systems Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medisim Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medimetrics S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments